In a new study, scientists were able to transform pluripotent stem cells into human hematopoietic stem and progenitor cells in mice. This feat could lead to new treatment options for people with genetic blood disorders.
This study, led by Deepak Kumar Jha and Aereum Han of Boston’s Children’s Hospital and Dana-Faber Cancer Institute, appeared in the journal Nature. The researchers used morphogens to differentiate human pluripotent cells into hemogenic endothelium. They also tested 26 potential defining factors in hematopoietic stem-cell transcription that could lead to multi-lineage engraftment of hematopoietic stem cells in mice.
The researchers identified seven transcription elements that can transform hemogenic endothelium into hemotopoietic and progenitor cells in mice. These cells could successfully produce myeloid as well as B and T lymphocytes.
Besides possibly leading to new ways to treat genetic blood conditions, this finding could also lead to a better understanding of hematopoietic disease in humanized mice.